ARIZ is a company dedicated to solving a big problem, cancer. We start at the beginning, the cause of cancer and design drugs that can resolve a specific individual cancer as well as all cancers. ARIZ Precision Medicine uses this methodology to design a specific way to stop the cause of cancer, then target and protect the delivery system and finally, concentrate the drug inside the cancer cell leaving normal cells undamaged.
Our scientists have dedicated a lifetime of research to develop a stable nanocarrier platforms for delivery of therapeutic and diagnostics agens with high potency and high accuracy. Our research is focused on the development of mucoadhesive protein-capsid-based drug delivery systems by drink. Astrid Pharma Corp offers solutions backed by ground-breaking scientific discoveries to make the "needle-free" drug administration dream, a reality.
Evolve BioSystems will develop and bring to market the next generation of microbiome-based solutions to establish, restore, and maintain a healthy human gut microbiome across a range of unmet clinical needs.
Gates Foundation invests in $40 million venture round by Davis-based company | Sacramento Business Journal, June 13, 2018
Group including Ranadivé invests $20 million in nutrition company | Sacramento Business Journal, May 30, 2017
We are addressing the opioid crisis in America and the vast unmet medical needs in pain management by developing a new class of pain drugs that was discovered by accident during our search for new and better general anesthetics. We are also working to reduce anesthetic costs and bring general anesthesia to the third of the world that lacks access through the development of new and better agents.
Davis-based Expanesthetics raises another $1.16 million in venture capital | Sacramento Business Journal, August 14, 2018
Davis-based Expanesthetics raises nearly $3 million | Sacramento Business Journal, September 25, 2017
Innovative skincare utilizing cytokines and growth factors derived from human stem cells to deliver unparalleled anti-aging results.
FEAT encourages children to start and maintain a healthy lifestyle by leveraging technology and their natural desire to play.
It involves developing and shaping a platform linking children to healthy behaviors through a reward system that promotes both activity and rest, while encouraging habit forming healthy play patterns like time in nature, time outside and creative serious play.
LearnSkin was developed by dermatologists and integrative medicine practitioners who wanted to support other professionals in dermatology, the number one driver of doctor's visits. Our goal is to share the latest in scientific research and treatment options in dermatology for both Western and Eastern medicine to meet the growing demand for responsible, high quality, evidence-based education that bridges conventional and alternative medical approaches. LearnSkin is supported by the world's largest integrative dermatology team.
Molecular Matrix, Inc. is focused on providing advanced research tools for cultivating and studying stem cells. Our products provide cutting edge solutions for growing cells in three dimensions. Our GroCell-3D™ product portfolio is comprised of 3D Scaffolds in various configurations, a cost effective dynamic cell culture system, and a solution to dissolve the scaffold and recover cells.
Startup of the Month: Molecular Matrix | Comstock's Magazine, April 4, 2018
Nivagen Pharmaceuticals is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Rancho Cordova-based pharmaceutical startup raises $10 million | Sacramento Business Journal, September 18, 2017
Protxx has developed wearable sensor technology for head injury prevention and management. The system helps to proactively limit cumulative head impact exposure.
How a local tech company plans to reduce head injury risk in sports | Sacramento Business Journal, March 1, 2018
Protxx uses technology to tackle head injury risk in youth sports | Sacramento Business Journal, March 15, 2018
